Ender Anılır Combined hepatocellular-cholangiocarcinoma

Published: 19-03-2021| Version 1 | DOI: 10.17632/px64fm2msc.1
Contributor:
Ender Anılır

Description

Investigation of combined hepatocellular-cholangiocarcinoma cases detected incidentally in patients who underwent liver transplantation for HCC.

Files

Steps to reproduce

Collected LT database was retrospectively reviewed. 277 patients underwent LT for a primary liver tumor between September 2004 and November 2019 in Demiroglu Bilim University Florence Nightingale Hospitals, were included in the study. Among these, 17 patients (5%) with incidentally detected CHC and 5 patients (1.8%) with ICCA were included in the study. 257 HCC patients were determined as the control group. The median follow up period was 16.1 months (range: 1-73 months) for CHC. Demographic data including age and gender, living donor liver transplantation (LDLT) and decaesed donor liver transplantation (DDLT) rates, blood groups rates were calculated and stated in the study. Gender, age, etiology, MELD, Child score, BMİ, CEA, AFP (ng/mL) and CA 19-9 (U/ml) values, Milan Criteria, T stage, tumor grade, presence of microvascular and vascular invasion, multicentricity, tumor number, maximum and total tumor size, recurrence, mortality, location of recurrence rates of CHC and CHC plus İCC patient groups were analyzed statistically for difference between CHC groups and HCC group. CK7, CK19, HSA, CD34, CD56, CD44, CD117, P53, arginaz values were analyased statistically in terms of whether there was a difference between HCC and CHC groups. Overall survival and disease free survival rates for 1, 3 and 5 years among HCC and CHC patients were analyzed statistically.